Pdt Partners, LLC Relay Therapeutics, Inc. Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 127,272 shares of RLAY stock, worth $572,724. This represents 0.09% of its overall portfolio holdings.

Number of Shares

127,272

Previous 226,632 43.84%

Holding current value

$572,724

Previous $1.48 Million 39.0%

% of portfolio

0.09%

Previous 0.15%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.23 - $9.51 $619,012 - $944,913	-99,360 Reduced 43.84%	127,272 $901,000
Q2 2024 Aug 15, 2024	BUY	$5.9 - $8.02 $434,481 - $590,600	73,641 Added 48.13%	226,632 $1.48 Million
Q1 2024 May 15, 2024	SELL	$7.5 - $12.07 $314,235 - $505,708	-41,898 Reduced 21.5%	152,991 $1.27 Million
Q4 2023 Feb 14, 2024	BUY	$6.01 - $11.48 $324,780 - $620,379	54,040 Added 38.37%	194,889 $2.15 Million
Q3 2023 Nov 14, 2023	BUY	$8.24 - $12.97 $970,317 - $1.53 Million	117,757 Added 509.95%	140,849 $1.18 Million
Q2 2023 Aug 14, 2023	BUY	$9.99 - $18.27 $230,689 - $421,890	23,092 New	23,092 $290,000
Q3 2022 Nov 14, 2022	SELL	$18.07 - $31.37 $1.79 Million - $3.11 Million	-99,198 Reduced 87.67%	13,953 $312,000
Q2 2022 Aug 15, 2022	BUY	$13.31 - $34.88 $877,355 - $2.3 Million	65,917 Added 139.55%	113,151 $1.9 Million
Q1 2022 May 16, 2022	SELL	$20.26 - $32.36 $463,265 - $739,943	-22,866 Reduced 32.62%	47,234 $1.41 Million
Q4 2021 Feb 14, 2022	SELL	$26.0 - $37.03 $456,352 - $649,950	-17,552 Reduced 20.02%	70,100 $2.15 Million
Q3 2021 Nov 15, 2021	BUY	$29.75 - $37.99 $2.61 Million - $3.33 Million	87,652 New	87,652 $2.76 Million

Others Institutions Holding RLAY

# of Institutions

204

Shares Held

156M

Call Options Held

207K

Put Options Held

40K

View Full List

About Relay Therapeutics, Inc.

Ticker RLAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 120,219,000
Market Cap $541M
Description
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...

More about RLAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account